Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$22.08
Change (%) Stock is Up 0.78 (3.66%)
Volume3,668,444
Data as of 04/25/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
04/24/17Exelixis to Present at the Deutsche Bank 42nd Annual Health Care Conference on May 3Printer Friendly Version
04/18/17Exelixis to Release First Quarter 2017 Financial Results on Monday, May 1, 2017Printer Friendly Version
04/04/17Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
03/29/17Exelixis Further Reduces Indebtedness by Repaying Silicon Valley Bank Term LoanPrinter Friendly Version
Upcoming EventsMore >>
Q1 2017 Exelixis Inc. Financial Results Conference Call
Monday, May 1, 2017 5:00 p.m. ET
Add to Calendar Add Q1 2017 Exelixis Inc. Financial Results Conference Call  to Calendar  Help
remind me days before the event

Exelixis, Inc. at Deutsche Bank’s Health Care Conference
Wednesday, May 3, 2017 11:20 a.m. ET
Add to Calendar Add Exelixis, Inc. at Deutsche Bank’s Health Care Conference to Calendar  Help
remind me days before the event

Enter your e-mail address 
Featured Report
Download Documentation2016 Annual Report (pdf)
Download Documentation2015 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.